| Mr Matthew Benjamin Burns, AG-ACNP | |
|
2900 Lamb Cir Ste 7-700a, Christiansburg, VA 24073-6344 | |
| (540) 731-7460 | |
| (540) 731-1081 |
| Full Name | Mr Matthew Benjamin Burns |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 2900 Lamb Cir Ste 7-700a, Christiansburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104495894 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 0024180593 (Virginia) | Secondary |
| 363LA2100X | Nurse Practitioner - Acute Care | 0024180593 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion New River Valley Medical Center | Christiansburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carilion Medical Center | 9830096585 | 758 |
News Archive
Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries' Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.
A team of researchers led by a member of the Colorado School of Public Health faculty at the Anschutz Medical Campus examined what type of social interaction is required for people to display physiological synchrony-mutual changes in autonomic nervous system activity.
Underscoring the value of good prenatal care, new research suggests that early infection may create a cognitive vulnerability that appears later during stress on the immune system.
A genetic test that helps predict whether some women's breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine.
› Verified 1 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries' Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.
A team of researchers led by a member of the Colorado School of Public Health faculty at the Anschutz Medical Campus examined what type of social interaction is required for people to display physiological synchrony-mutual changes in autonomic nervous system activity.
Underscoring the value of good prenatal care, new research suggests that early infection may create a cognitive vulnerability that appears later during stress on the immune system.
A genetic test that helps predict whether some women's breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine.
› Verified 1 days ago
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries' Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.
A team of researchers led by a member of the Colorado School of Public Health faculty at the Anschutz Medical Campus examined what type of social interaction is required for people to display physiological synchrony-mutual changes in autonomic nervous system activity.
Underscoring the value of good prenatal care, new research suggests that early infection may create a cognitive vulnerability that appears later during stress on the immune system.
A genetic test that helps predict whether some women's breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine.
› Verified 1 days ago
| Entity Name | Carilion Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123472 PECOS PAC ID: 9830096585 Enrollment ID: O20040107000472 |
News Archive
Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries' Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.
A team of researchers led by a member of the Colorado School of Public Health faculty at the Anschutz Medical Campus examined what type of social interaction is required for people to display physiological synchrony-mutual changes in autonomic nervous system activity.
Underscoring the value of good prenatal care, new research suggests that early infection may create a cognitive vulnerability that appears later during stress on the immune system.
A genetic test that helps predict whether some women's breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Matthew Benjamin Burns, AG-ACNP 213 S Jefferson St Ste 1006, Roanoke, VA 24011-1713 Ph: (540) 224-5352 | Mr Matthew Benjamin Burns, AG-ACNP 2900 Lamb Cir Ste 7-700a, Christiansburg, VA 24073-6344 Ph: (540) 731-7460 |
News Archive
Biogen Idec Inc. has reported success in a late stage clinical trial of its oral multiple sclerosis drug BG-12, a competitor's of Teva Pharmaceutical Industries' Laquinimod. A 240-milligram dose of BG-12 administered two or three times a day significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively, after two years compared with a placebo.
A team of researchers led by a member of the Colorado School of Public Health faculty at the Anschutz Medical Campus examined what type of social interaction is required for people to display physiological synchrony-mutual changes in autonomic nervous system activity.
Underscoring the value of good prenatal care, new research suggests that early infection may create a cognitive vulnerability that appears later during stress on the immune system.
A genetic test that helps predict whether some women's breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine.
› Verified 1 days ago